Details of the Drug

General Information of Drug (ID: DMKV4NL)

Drug Name

Flavoxate

Synonyms

Bladuril; Flavossato; Flavoxato; Flavoxatum; Urispas; Flavossato [DCIT]; Flavoxate HCI; Flavoxate HCL; Spasuret hydrochloride; AK 123; Bladderon (TN); Bladuril (TN); DW-61; Flavoxate (INN); Flavoxate [INN:BAN]; Flavoxato [INN-Spanish]; Flavoxatum [INN-Latin]; Urispas (TN); Uritac (TN); Zopyran-8-carboxylate; Beta-piperidinoethyl 3-methylflavone-8-carboxylate; Piperidinoethyl-3-methylflavone-8-carboxylate; 1-Piperidinoethanol, 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylate; 2-(1-Piperidinyl)ethyl 3-methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylate; 2-(piperidin-1-yl)ethyl 3-methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylate; 2-Piperidinoethyl 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylat; 2-Piperidinoethyl 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylate; 2-Piperidinoethyl-3-methyl-4-oxo-2-phenyl-4H-1-ben; 2-piperidin-1-ylethyl 3-methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylate; 2-piperidin-1-ylethyl 3-methyl-4-oxo-2-phenylchromene-8-carboxylate; 2-piperidinoethyl 3-methylflavone-8-carboxylate; 4H-1-Benzopyran-8-carboxylic acid, 3-methyl-4-oxo-2-phenyl-, 2-(1-piperidinyl)ethyl ester

Indication

Disease Entry	ICD 11	Status	REF
Dysuria	MF50.7	Approved	[1]
Nocturia	MF55	Approved	[1]
Suprapubic pain	MG30-MG3Z	Approved	[1]
Urgency	N.A.	Approved	[1]

Therapeutic Class

Parasympatholytics

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

391.5

Topological Polar Surface Area (xlogp)

4.3

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption: The drug is well absorbed from the gastrointestinal tract [2]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]

Chemical Identifiers

Formula: C24H25NO4
IUPAC Name: 2-piperidin-1-ylethyl 3-methyl-4-oxo-2-phenylchromene-8-carboxylate
Canonical SMILES: CC1=C(OC2=C(C1=O)C=CC=C2C(=O)OCCN3CCCCC3)C4=CC=CC=C4
InChI: InChI=1S/C24H25NO4/c1-17-21(26)19-11-8-12-20(23(19)29-22(17)18-9-4-2-5-10-18)24(27)28-16-15-25-13-6-3-7-14-25/h2,4-5,8-12H,3,6-7,13-16H2,1H3
InChIKey: SPIUTQOUKAMGCX-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 3354
ChEBI ID: CHEBI:5088
CAS Number: 15301-69-6
DrugBank ID: DB01148
TTD ID: D0ND2J
VARIDT ID: DR00726
ACDINA ID: D00277

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Muscarinic acetylcholine receptor M5 (CHRM5)	TTH18TF	ACM5_HUMAN	Antagonist	[4]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Flavoxate

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Oxymorphone	DM65AGJ	Moderate	Additive antimotility effects by the combination of Flavoxate and Oxymorphone.	Pain [MG30-MG3Z]	[15]
Dezocine	DMJDB0Y	Moderate	Additive antimotility effects by the combination of Flavoxate and Dezocine.	Pain [MG30-MG3Z]	[15]
-----------

Coadministration of a Drug Treating the Disease Different from Flavoxate (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Oliceridine	DM6MDCF	Moderate	Additive antimotility effects by the combination of Flavoxate and Oliceridine.	Acute pain [MG31]	[15]
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Flavoxate and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[16]
Phenyltoloxamine	DMKAEQW	Moderate	Additive anticholinergic effects by the combination of Flavoxate and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[16]
Desipramine	DMT2FDC	Moderate	Additive anticholinergic effects by the combination of Flavoxate and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[17]
Cariprazine	DMJYDVK	Moderate	Additive anticholinergic effects by the combination of Flavoxate and Cariprazine.	Bipolar disorder [6A60]	[17]
Acetylcholine	DMDF79Z	Moderate	Antagonize the effect of Flavoxate when combined with Acetylcholine.	Cataract [9B10]	[18]
Umeclidinium	DM4E8O9	Moderate	Additive anticholinergic effects by the combination of Flavoxate and Umeclidinium.	Chronic obstructive pulmonary disease [CA22]	[19]
Tiotropium	DMFDC0Q	Moderate	Additive anticholinergic effects by the combination of Flavoxate and Tiotropium.	Chronic obstructive pulmonary disease [CA22]	[19]
Revefenacin	DMMP5SI	Moderate	Additive anticholinergic effects by the combination of Flavoxate and Revefenacin.	Chronic obstructive pulmonary disease [CA22]	[19]
OPC-34712	DMHG57U	Moderate	Additive anticholinergic effects by the combination of Flavoxate and OPC-34712.	Depression [6A70-6A7Z]	[17]
Clomipramine	DMINRKW	Moderate	Additive anticholinergic effects by the combination of Flavoxate and Clomipramine.	Depression [6A70-6A7Z]	[17]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Flavoxate and Esketamine.	Depression [6A70-6A7Z]	[20]
Mepenzolate	DM8YU2F	Moderate	Additive anticholinergic effects by the combination of Flavoxate and Mepenzolate.	Digestive system disease [DE2Z]	[17]
Solifenacin	DMG592Q	Moderate	Additive anticholinergic effects by the combination of Flavoxate and Solifenacin.	Functional bladder disorder [GC50]	[17]
Belladonna	DM2RBWK	Moderate	Additive anticholinergic effects by the combination of Flavoxate and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[17]
ITI-007	DMUQ1DO	Moderate	Additive anticholinergic effects by the combination of Flavoxate and ITI-007.	Insomnia [7A00-7A0Z]	[17]
R0-93877	DMM4U9G	Moderate	Antagonize the effect of Flavoxate when combined with R0-93877.	Irritable bowel syndrome [DD91]	[21]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Flavoxate and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[22]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Flavoxate and Lasmiditan.	Migraine [8A80]	[23]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Flavoxate and Flibanserin.	Mood disorder [6A60-6E23]	[24]
Neostigmine	DM6T2J3	Moderate	Antagonize the effect of Flavoxate when combined with Neostigmine.	Myasthenia gravis [8C6Y]	[25]
Phenindamine	DMDTC7R	Moderate	Additive anticholinergic effects by the combination of Flavoxate and Phenindamine.	Nasopharyngitis [CA00]	[17]
Cyclizine	DM9G7BS	Moderate	Additive anticholinergic effects by the combination of Flavoxate and Cyclizine.	Nausea/vomiting [MD90]	[17]
Metoclopramide	DMFA5MY	Moderate	Antagonize the effect of Flavoxate when combined with Metoclopramide.	Nausea/vomiting [MD90]	[26]
Polythiazide	DMCH80F	Minor	Altered absorption of Flavoxate due to GI dynamics variation caused by Polythiazide.	Oedema [MG29]	[27]
Levomethadyl Acetate	DM06HG5	Moderate	Additive antimotility effects by the combination of Flavoxate and Levomethadyl Acetate.	Opioid use disorder [6C43]	[28]
Levodopa	DMN3E57	Moderate	Altered absorption of Flavoxate due to GI dynamics variation caused by Levodopa.	Parkinsonism [8A00]	[29]
Orphenadrine	DMW542E	Moderate	Additive anticholinergic effects by the combination of Flavoxate and Orphenadrine.	Parkinsonism [8A00]	[17]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Flavoxate and Methylscopolamine.	Peptic ulcer [DA61]	[17]
Levomepromazine	DMIKFEL	Moderate	Additive anticholinergic effects by the combination of Flavoxate and Levomepromazine.	Psychotic disorder [6A20-6A25]	[17]
Quetiapine	DM1N62C	Moderate	Additive anticholinergic effects by the combination of Flavoxate and Quetiapine.	Schizophrenia [6A20]	[17]
Aripiprazole	DM3NUMH	Moderate	Additive anticholinergic effects by the combination of Flavoxate and Aripiprazole.	Schizophrenia [6A20]	[17]
Iloperidone	DM6AUFY	Moderate	Additive anticholinergic effects by the combination of Flavoxate and Iloperidone.	Schizophrenia [6A20]	[17]
Paliperidone	DM7NPJS	Moderate	Additive anticholinergic effects by the combination of Flavoxate and Paliperidone.	Schizophrenia [6A20]	[17]
Molindone	DMAH70G	Moderate	Additive anticholinergic effects by the combination of Flavoxate and Molindone.	Schizophrenia [6A20]	[17]
Thiothixene	DMDINC4	Moderate	Additive anticholinergic effects by the combination of Flavoxate and Thiothixene.	Schizophrenia [6A20]	[17]
Asenapine	DMSQZE2	Moderate	Additive anticholinergic effects by the combination of Flavoxate and Asenapine.	Schizophrenia [6A20]	[17]
Pramlintide	DM0EZ9Q	Moderate	Altered absorption of Flavoxate due to GI dynamics variation caused by Pramlintide.	Type-1/2 diabete [5A10-5A11]	[30]
Trimeprazine	DMEMV9D	Moderate	Additive anticholinergic effects by the combination of Flavoxate and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[16]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Flavoxate and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[17]
-----------


⏷ Show the Full List of 40 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Ethyl acrylate	E00191	8821	Film/membrane-forming agent; Flavoring agent
Brushite	E00392	104805	Diluent
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Methyl methacrylate	E00133	6658	Film/membrane-forming agent
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
--------------------


⏷ Show the Full List of 10 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Flavoxate Hydrochloride 100mg tablet	100mg	Tablet	Oral
Flavoxate 100 mg tablet	100 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
3	BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
4	Brain pertussis toxin-sensitive G proteins are involved in the flavoxate hydrochloride-induced suppression of the micturition reflex in rats. Brain Res. 1996 Jul 15;727(1-2):91-8.
5	Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci. 1988;43(5):405-12.
6	Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7.
7	Retinoic acid prevents virus-induced airway hyperreactivity and M2 receptor dysfunction via anti-inflammatory and antiviral effects. Am J Physiol Lung Cell Mol Physiol. 2009 Aug;297(2):L340-6.
8	Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81.
9	Additive protective effects of donepezil and nicotine against salsolinol-induced cytotoxicity in SH-SY5Y cells. Neurotox Res. 2009 Oct;16(3):194-204.
10	Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci. 1999;64(25):2351-8.
11	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7354).
12	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
13	Comparison of pharmacological effects of L- and DL-n-butyl-scopolamine in rat uterus. Yao Xue Xue Bao. 1994;29(1):24-7.
14	Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
15	Product Information. Apadaz (acetaminophen-benzhydrocodone). KemPharm, Inc, Coralville, IA.
16	Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
17	Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
18	Multum Information Services, Inc. Expert Review Panel.
19	Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
20	Cerner Multum, Inc. "Australian Product Information.".
21	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
22	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
23	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
24	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
25	Product Information. Mestinon (pyridostigmine). ICN Pharmaceuticals Inc, Cost Mesa, CA.
26	Product Information. Motilium (domperidone). Janssen-Ortho Inc, Toronto, ON.
27	Beermann B, Groschinsky-Grind M "Enhancement of the gastrointestinal absorption of hydrochlorothiazide by propantheline." Eur J Clin Pharmacol 13 (1978): 385-7. [PMID: 668798]
28	Product Information. Exalgo (hydromorphone). Covidien, Mansfield, MA.
29	Algeri S, Cerletti C, Curcio M, et al. "Effect of anticholinergic drugs on gastro-intestinal absorption of L-dopa in rats and man." Eur J Pharmacol 35 (1976): 293-9. [PMID: 1248506]
30	Product Information. Symlin (pramlintide). Amphastar Pharmaceuticals Inc, South El Monte, CA.